We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05182931
Recruitment Status : Recruiting
First Posted : January 10, 2022
Last Update Posted : August 1, 2022
Sponsor:
Collaborators:
Royal North Shore Hospital
Austin Health
Sir Charles Gairdner Hospital
Monash Health
Peter MacCallum Cancer Centre, Australia
Royal Brisbane and Women's Hospital
Eastern Health
The Alfred
Information provided by (Responsible Party):
Olivia Newton-John Cancer Research Institute

Brief Summary:

This prospective, multi-centre, open label, non-randomised phase II trial aims restore radioiodine sensitivity in patients with NRAS or BRAFV600E mutant refractory thyroid cancer.

Participants will be treated with Trametinib +/- Dabrafenib tyrosine kinase inhibitors for a period of 30 days, restoration of sensitivity will be monitored using 18F-FDG-PET & I-124 PET imaging.


Condition or disease Intervention/treatment Phase
Thyroid Cancer Drug: Dabrafenib 75 MG Drug: Trametinib 2 MG Phase 2

Detailed Description:

This is a prospective, non-randomised, multi-centre study which will be conducted at 10 sites around Australia.

Adult patients (18+ years) with radioiodine refractory differentiated thyroid cancer with BRAF V600E or NRAS mutant RECIST 1.1 evaluable tumours will be eligible to participate. .

All eligible patients will undergo a 18F-FDG PET/CT scan during the registration period (day -28), followed by T4 withdrawal and low iodine diet. T3 will be administered after T4 withdrawal and for up to 10 days prior to the 124I dose to minimise symptoms of hypothyroidism.

The first 124I dose will be administered orally at a dose of 40 MBq (1.08 mCi) on day -5 with a 18FDG-PET performed on the same day. Patients will then have 124I-PET imaging and bloods at 24 hrs (+/- 6 hrs) post-dose, with a second imaging time-point up until 120 hours post- 124I dose. The initial 124I study (pre-TKI) will serve as a baseline for the second 124I-PET (day 24, after 23 days of TKI), and demonstrate changes in NIS expression and radioiodine uptake as a result of TKI treatment.

Patients will then commence a total of 30 days of treatment with the MEK TKI trametinib (for NRAS mutant tumours) or the MEK and BRAF V600E TKI combination of trametinib and dabrafenib (for BRAF V600E mutant tumours). Patients will then have a further 18F-FDG PET/CT scan and 124I dose on day 23, and scans for dosimetry (124I-PET) at 24 hrs (+/- 6 hrs) post-dose (day 24), with a second imaging time-point up until 120 hours post-124I administration. If at least one lesion shows uptake on 124I scans consistent with > 20Gy / 6GBq (3.3Gy/GBq) 131I administered (based on the 24-hour scan), then 131I treatment will be administered on day 29. The dose of 131I administered will be fixed at 6 GBq (150 mCi) to allow for evaluation of dose response. TKI treatment will continue until the day after 131I treatment is given (total 30 days).

Follow-up staging (CT) will occur every 3 months for the first 24 months, then every 6 months until progression, and 18F-FDG PET at 6 and 12 months. Non-stimulated thyroglobulin (Tg) will also be measured at 3, 6, 9 and 12 months, and evaluated as a percentage change from baseline. QoL and health economic data will be collected in all patients going on study. Overall survival will be obtained by long-term follow-up. Central review of tumour mutations, 124I PET dosimetry, staging (RECIST) and 18F-FDG PET (PERCIST) will be performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants with BRAF V600E mutant thyroid cancer will receive Dabrafenib + Trametinib; Participants with RAS mutant thyroid cancer will receive Trametinib alone.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Actual Study Start Date : July 14, 2022
Estimated Primary Completion Date : December 30, 2024
Estimated Study Completion Date : December 30, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BRAFv600E mutant radioiodine refractory thyroid cancer

Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.

Participants will receive Dabrafenib (oral, 150mg BD) and Trametinib (oral, 2mg OD) from day 1-30.

A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.

Participants achieving >20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.

Participants who do not achieve >20Gy tumour update of I-124 will move into follow up.

Follow up will occur every 12 weeks for 12 months.

Drug: Dabrafenib 75 MG
Refer arm description
Other Name: Tafinlar

Drug: Trametinib 2 MG
Refer arm description
Other Name: Mekinist

Experimental: RAS mutant radioiodine refractory thyroid cancer

Prior to commencing interventional treatment, participants will commence a low iodine diet and undergo thyroxine withdrawal and commence T3 replacement from day -27. On day -5 they will receive an oral dose of 124I (40MBq/1.08 mCi) with imaging at 24 hours (+/-6) post dose and a second imaging assessment within 120 hours.

Participants will receive Trametinib (oral, 2mg OD) from day 1-30.

A second oral dose of I124 will be administered at day 24 followed by imaging at the same interval as baseline.

Participants achieving >20Gy tumour uptake of I124 will be administered 6GBq (3.3Gy/GBq) 131I, I131 wb scan and SPECT/CT will be performed within 24 hours and at hospital discharge.

Participants who do not achieve >20Gy tumour update of I-124 will move into follow up.

Follow up will occur every 12 weeks for 12 months.

Drug: Trametinib 2 MG
Refer arm description
Other Name: Mekinist




Primary Outcome Measures :
  1. Progression free survival as assessed by RECIST 1.1 criteria at 6 months in participants who proceed to I131 treatment [ Time Frame: At 6 months following day 1. ]
    Radioiodine refractory thyroid cancer patients able to proceed to 131I treatment will be assessed by RECIST 1.1 criteria.

  2. Progression free survival as assessed by RECIST 1.1 criteria at 12 months in participants who proceed to I131 treatment [ Time Frame: At 12 months following day 1. ]
    Radioiodine refractory thyroid cancer patients able to proceed to 131I treatment will be assessed by RECIST 1.1 criteria.


Secondary Outcome Measures :
  1. Progression free survival as assessed by RECIST 1.1 criteria at 6 months in all participants and a control population (SELECT study) [ Time Frame: At 6 months following day 1. ]

    To assess PFS by RECIST v1.1 at 6 in radioiodine-refractory thyroid cancer patients able to proceed to 131I treatment following TKI redifferentiation therapy,

    1. compared to those who do not proceed to 131I treatment.
    2. compared to a control population (from the SELECT study).

  2. Progression free survival as assessed by RECIST 1.1 criteria at 12 months in all participants and a control population (SELECT study) [ Time Frame: At 12 months following day 1. ]

    To assess PFS by RECIST v1.1 at 12 months in radioiodine-refractory thyroid cancer patients able to proceed to 131I treatment following TKI redifferentiation therapy,

    1. compared to those who do not proceed to 131I treatment.
    2. compared to a control population (from the SELECT study).

  3. Objective response rate by RECIST 1.1 criteria in all treated participants [ Time Frame: 0-18 months or at PD ]
    To assess objective response (CR/PR/SD) in all treated participants from time of enrolment until 18 months or PD.

  4. Overall survival of treated participants [ Time Frame: From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. ]
    To confirm the overall survival of participants receiving treatment on study via Kaplan-Meier estimation.

  5. Quantification of treatment related toxicities according to CTCAE V5.0 [ Time Frame: From day -27 until 30 days following last dose [up to max 60 days]. ]
    Quantification of treatment related toxicities according to CTCAE V5.0

  6. Quantification of radioiodine uptake in metastatic lesions before and after TKI treatment. [ Time Frame: From day -5 until day 30 on study. ]
    Quantification of radioiodine uptake in metastatic lesions before and after TKI treatment.

  7. Evaluation of response to treatment by percent change from baseline of non-stimulated thyroglobulin. [ Time Frame: Day 0; 3, 6, 9, 12 months in participants without radiological progression. ]
    Evaluation of response to treatment by percent change from baseline of non-stimulated thyroglobulin.

  8. Evaluation and comparison of quality of life as measured by response to EORTC-QLQ-C30 in participants on study. [ Time Frame: Day -29, 1, 29; 3, 6, 9, 12 months. ]
    Evaluation of QOL in participants who proceed to I131 treatment compared with participants who proceed to follow up only by EORTC-QLQ-C30. Scores are from 0-100 with participant reported quality of live improving with a higher score.

  9. Evaluation and comparison of QOL as measured by response to EQ-5D-5L in participants on study. [ Time Frame: Day -29, 1, 29; 3, 6, 9, 12 months. ]
    In participants who proceed to I131 treatment compared with follow up only by EQ-5D-5L. Five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems to extreme problems.

  10. Evaluation and comparison of QOL as measured by response to Kessler Psychological Distress Scale (K10) in participants on study. [ Time Frame: Day -29, 1, 29; 3, 6, 9, 12 months. ]
    In participants who proceed to I131 treatment compared with follow up only by responses to the Kessler Psychological Distress Scale (K10). This is a 10-item questionnaire yielding a global measure of distress based on questions about anxiety and depressive symptoms. 5 levels ranging from none of the time to all of the time, higher level responses correspond with greater reported distress.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically-confirmed differentiated (including poorly differentiated) thyroid cancer that is either locally advanced or metastatic.
  2. Age > 18 years.
  3. Life expectancy > 12 weeks.
  4. Documented radiological progression by RECIST 1.1 in last 12 months.
  5. Radioiodine refractory (at least one of):

    1. one measurable lesion without radioiodine uptake on 131I scan,
    2. at least one measurable lesion that had progressed by RECIST criteria within 12 months of 131I therapy despite 131I avidity at time of treatment, or
    3. cumulative treatment with >24 GBq (600 mCi) of 131I.
  6. At least one evaluable lesion as per RECIST v1.1 that has not been treated with local radiation therapy within 3 months prior to the first dose of TKI. Irradiated lesions can only be included as an evaluable lesion if it has shown radiological progression as per RECIST v1.1 on subsequent imaging following irradiation.
  7. NRAS or BRAF V600E mutation tested by NGS in a NATA accredited laboratory or by recognised sequencing platform.
  8. ECOG 0-1.
  9. Informed consent.
  10. Adequate haematological and biochemical parameters:

    1. Haemoglobin ≥ 9g/dL
    2. Neutrophils ≥ 1.5 x 109/L
    3. Platelets ≥ 100 x 109/L
    4. INR ≤ 1.4
    5. Serum Creatinine ≤ 1.3 x ULN
    6. Estimated Creatinine Clearance ≥ 30 ml/min (by Cockcroft Gault Formula)
    7. Serum ALT and AST ≤ 2.5 x ULN
    8. Serum Total Bilirubin ≤ 1.5 x ULN.
    9. TSH suppression <0.1mU/L or otherwise consistent with 2015 ATA Guidelines on Thyroid Cancer

Exclusion Criteria:

  1. Anaplastic thyroid cancer.
  2. Suitable for curative surgery or radiotherapy.
  3. Other anti-cancer (including TKI) therapy in prior 6 weeks.
  4. Concurrent malignancy other than non-melanoma skin cancer. Prior malignancies treated with curative intent and no evidence of recurrence in past three years may be allowed upon discussion with the medical monitor.
  5. Unstable brain metastasis. Treated or non-treated brain metastasis are allowed if neurologically stable, asymptomatic, on a stable steroid dose for a period of 2 weeks, and not anticipated to require any intervention during the trial treatment period. If treated with radiation or surgery, any related AE's should have recovered to ≤ grade 1 prior to enrolment on trial.
  6. Pregnancy, breastfeeding or unwilling to use contraception in those of child-bearing age.
  7. Significant medical condition that would prevent compliance with study procedures.
  8. History of retinal vein occlusion or retinopathy.
  9. Iodine-containing contrast scan within 8 weeks of planned 124I scan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05182931


Contacts
Layout table for location contacts
Contact: Jodie Palmer, PhD +61394963573 trials@onjcri.org.au

Locations
Layout table for location information
Australia, New South Wales
Royal North Shore Hospital Recruiting
Sydney, New South Wales, Australia
Contact: Roderick Clifton-Bligh, MBBS, FRACP         
Principal Investigator: Roderick Clifton-Bligh, MBBS         
Sub-Investigator: Bruce Robinson, MBBS, FRACP         
Australia, Queensland
Royal Brisbane and Women's Hospital Not yet recruiting
Brisbane, Queensland, Australia, 4029
Contact: David Pattison, MBBS, FRACP         
Principal Investigator: David Pattison, MBBS, FRACP         
Principal Investigator: Donald McLeod, MBBS, FRACP         
Australia, Victoria
Eastern Health Not yet recruiting
Box Hill, Victoria, Australia, 3128
Contact: Chris Gillfilan, MBBS         
Principal Investigator: Chris Gillfilan, MBBS         
Monash Health Not yet recruiting
Clayton, Victoria, Australia, 3168
Contact: Michael Mond, MBBS         
Principal Investigator: Michael Mond, MBBS, FRACP         
Austin Health Recruiting
Heidelberg, Victoria, Australia, 3084
Contact: Andrew M Scott, MD, FRACP         
Principal Investigator: Andrew M Scott, MBBS, FRACP         
Alfred Hospital Not yet recruiting
Prahran, Victoria, Australia
Contact: Duncan Topliss, MBBS, FRACP         
Principal Investigator: Duncan Topliss, MBBS, FRACP         
Australia, Western Australia
Sir Charles Gairdner Hospital Not yet recruiting
Perth, Western Australia, Australia
Contact: Roslyn Francis, MBBS, FRACP         
Principal Investigator: Roslyn Francis, MBBS, FRACP         
Australia
Peter MacCallum Cancer Centre Not yet recruiting
Melbourne, Australia
Contact: Annette Lim, MBBS, FRACP         
Principal Investigator: Annette Lim, MBBS, FRACP         
Sponsors and Collaborators
Olivia Newton-John Cancer Research Institute
Royal North Shore Hospital
Austin Health
Sir Charles Gairdner Hospital
Monash Health
Peter MacCallum Cancer Centre, Australia
Royal Brisbane and Women's Hospital
Eastern Health
The Alfred
Investigators
Layout table for investigator information
Study Chair: Andrew M Scott, MD, FRACP Austin Health
Layout table for additonal information
Responsible Party: Olivia Newton-John Cancer Research Institute
ClinicalTrials.gov Identifier: NCT05182931    
Other Study ID Numbers: ONJ2021-006
First Posted: January 10, 2022    Key Record Dates
Last Update Posted: August 1, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Olivia Newton-John Cancer Research Institute:
Radioiodine refractory
BRAF600E mutant
RAS mutant
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Trametinib
Dabrafenib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action